Acadian Asset Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Acadian Asset Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,279	Closed	-$26K	–	1843
2021 Q4	$26K	Buy	+8,279	New	+$28.3K	﹤0.01%	1577
2020 Q3	–	Sell	-29,454	Closed	-$66K	–	2395
2020 Q2	$66K	Sell	29,454 -106,871	-78%	-$275K	﹤0.01%	1844
2020 Q1	$345K	Sell	136,325 -12,458	-8%	-$30.6K	﹤0.01%	1057
2019 Q4	$391K	Sell	148,783 -26,326	-15%	-$78.6K	﹤0.01%	1133
2019 Q3	$631K	Sell	175,109 -10,162	-5%	-$36K	﹤0.01%	1022
2019 Q2	$625K	Sell	185,271 -135,791	-42%	-$478K	﹤0.01%	941
2019 Q1	$876K	Sell	321,062 -79,138	-20%	-$259K	﹤0.01%	934
2018 Q4	$1.11M	Sell	400,200 -58,850	-13%	-$193K	0.01%	712
2018 Q3	$1.89M	Sell	459,050 -21,866	-5%	-$99.3K	0.01%	574
2018 Q2	$2.49M	Sell	480,916 -66,893	-12%	-$408K	0.01%	511
2018 Q1	$3M	Sell	547,809 -368,112	-40%	-$2.59M	0.01%	513
2017 Q4	$7.46M	Sell	915,921 -84,805	-8%	-$810K	0.03%	314
2017 Q3	$10.5M	Sell	1,000,726 -101,822	-9%	-$1.13M	0.05%	274
2017 Q2	$12.2M	Sell	1,102,548 -88,257	-7%	-$822K	0.06%	256
2017 Q1	$9.97M	Sell	1,190,805 -14,128	-1%	-$99.5K	0.05%	284
2016 Q4	$8.36M	Sell	1,204,933 -44,109	-4%	-$281K	0.04%	318
2016 Q3	$6.36M	Sell	1,249,042 -56,335	-4%	-$336K	0.03%	334
2016 Q2	$7.79M	Sell	1,305,377 -33,337	-2%	-$185K	0.04%	288
2016 Q1	$6.09M	Buy	1,338,714 +778,759	+139%	+$3.47M	0.03%	367
2015 Q4	$2.52M	Buy	559,955 +513,009	+1,093%	+$2.17M	0.01%	533
2015 Q3	$149K	Sell	46,946 -41,499	-47%	-$126K	﹤0.01%	943
2015 Q2	$268K	Sell	88,445 -172,879	-66%	-$486K	﹤0.01%	888
2015 Q1	$770K	Buy	261,324 +12,984	+5%	+$42.5K	﹤0.01%	692
2014 Q4	$1.1M	Buy	248,340 +371	+0.1%	+$1.77K	﹤0.01%	622
2014 Q3	$1.28M	Buy	247,969 +135,862	+121%	+$725K	0.01%	545
2014 Q2	$588K	Buy	+112,107	New	+$485K	﹤0.01%	676

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCA

VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Acadian Asset Management's ENZ Position: Q1 2022 in Review

Acadian Asset Management sold out of Enzo Biochem, Inc. (ENZ) in Q1 2022, closing a stake of 8,279 shares — an estimated $26K sold.

Acadian Asset Management first reported a position in ENZ in Q2 2014 and held it in 26 quarters. The position peaked at $12.2M in Q2 2017. 51 funds tracked by Wall St. Rank hold ENZ as of Q1 2022.

Acadian Asset Management reported no remaining Enzo Biochem, Inc. position as of Q1 2022 after selling out during the quarter.
Acadian Asset Management sold 8,279 Enzo Biochem, Inc. shares in Q1 2022, an estimated $26K.
Acadian Asset Management first reported a position in Enzo Biochem, Inc. in Q2 2014 and held it in 26 quarters.
Acadian Asset Management's Enzo Biochem, Inc. position peaked at $12.2M in Q2 2017.
51 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2022.

Based on Acadian Asset Management's 13F filing for Q1 2022, filed 12 May 2022.